Press news Biocartis Group NV: New US Studies Demonstrate Idylla™ Allows Rapid First Assessment of Most Common EGFR Mutations Preceding Next-Generation Sequencing


You May Also Like

The New England Journal of Medicine Publishes Two Articles on Trogarzo™

Phase III results and FDA-authored article featured in latest edition of NEJMMONTREAL, Aug. 15, ...

Helix BioPharma Corp. Closes Private Placement

RICHMOND HILL, Ontario, June 07, 2018 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX:HBP) FSE:HBP) ...